Incyte Corporation

INCY

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (Ruxolitinib): Apr 2009. Short interest: 8.4% of float.

BiotechnologyCEO: William J. MeuryIPO: 1993Website ↗

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Catalysts

Phase 2PositiveQ2 2009RuxolitinibPsoriasisNCT00617994

Primary: Number of Treatment of Emergent Adverse Events (Approximately 3 months)Enrollment:25/25Sites: 4NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2010RuxolitinibMyeloproliferative Neoplasm (MPN)NCT00726232

Primary: Percentage of Polycythemia Vera Participants With a Confirmed Clinical Partial Response (PR) or Complete Response (CR) (Assessed after 2 cycles (56 days) of treatment on Day 1 of Cycle 3)Enrollment:73/73Sites: 4RANDOMIZED, TREATMENT

Phase 2Q1 2013ItacitinibPlaque PsoriasisNCT01634087

Primary: Safety and tolerability of itacitinib as measured by changes in frequency and severity of adverse events, ECGs, physical examination, vital signs, and clinical laboratory evaluations. (Approximately two months.)Enrollment:50/50Sites: 9RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ2 2018NivolumabLung CancerNCT03348904

Primary: Overall Survival (OS) of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Arm A) Compared to Chemotherapy (Arm B) (Approximately 38 months)Enrollment:2/2Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ1 2019PembrolizumabLung CancerNCT03322540

Primary: Objective Response Rate (ORR) of Pembrolizumab Plus Epacadostat Versus Pembrolizumab Plus Placebo (Up to approximately 6 months)Enrollment:154/154Sites: 101RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2019MEDI4736Solid Tumors, Head and Neck Cancer, Lung CancerNCT02318277

Primary: Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE) (Duration of study treatment and up to 90 days after the last dose [approximately 3 years])Enrollment:176/176Sites: 13NA, TREATMENT

Phase 2NegativeQ2 2020NivolumabB-cell Malignancies, Colorectal Cancer (CRC), Head and Neck CancerNCT02327078

Primary: Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) (Day 42)Enrollment:307/307Sites: 24NON_RANDOMIZED, TREATMENT

Phase 2Q1 2021ParsaclisibLymphomaNCT03144674

Phase 3Apr 24, 2022BaricitinibAtopic DermatitisNCT03952559

Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement (Week 16)Enrollment:516/516Sites: 78RANDOMIZED, DOUBLE, TREATMENT

Phase 2Sep 8, 2022INCMGA00012GlioblastomaNCT04225039

Primary: Objective Radiographic Response (ORR) (26 months)Enrollment:39/39Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Sep 19, 2022RuxolitinibChronic Myelomonocytic Leukemia, LeukemiaNCT03722407

Primary: Overall Response (At week 16)Enrollment:29/29Sites: 5NA, TREATMENT

Phase 2PositiveQ4 2022Ruxolitinib creamVitiligoNCT04896385

Primary: Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24 (Baseline; Week 4, Week 12, and Week 24)Enrollment:60/60Sites: 13RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ4 2022ruxolitinib creamAtopic DermatitisNCT04839380

Primary: Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application) (Baseline; Day 2)Enrollment:49/49Sites: 2NA, TREATMENT

Phase 2Dec 2, 2022ruxolitinibOther CancerNCT03674047

Primary: absolute FEV1 increase (3 Months)Enrollment:50/50Sites: 7NON_RANDOMIZED, TREATMENT

Phase 2Dec 28, 2022BusulfanPrimary Myelofibrosis, Secondary MyelofibrosisNCT02251821

Primary: 2-year Overall Survival (OS) in Patients With Myelofibrosis (MF) Who Receive Treatment With a JAK Inhibitor Followed by an Allogeneic Transplant (2 years)Enrollment:61/61Sites: 1NA, TREATMENT

Phase 2Dec 31, 2022RuxolitinibInflammatory Breast Cancer (IBC)NCT02876302

Primary: Biologic Response To 7-Day Run-In Window Phase Treatment of Ruxolitinib Alone or Ruxolitinib Plus Paclitaxel (7 days)Enrollment:23/23Sites: 4RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2023INCB054707Prurigo NodularisNCT05061693

Phase 3PositiveQ4 2023RetifanlimabMetastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung CancerNCT04205812

Primary: Overall Survival (up to 39.1 months)Enrollment:583/583Sites: 140RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2024tafasitamabFollicular Lymphoma, Marginal Zone LymphomaNCT04680052

Primary: FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First (up to approximately 34 months)Enrollment:654/654Sites: 261RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2024INCB086550Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell CarcinomaNCT04629339

Primary: Objective Response Rate (ORR) (up to 733 days)Enrollment:16/16Sites: 20NA, TREATMENT

Phase 2Q3 2024TafasitamabDiffuse Large B Cell LymphomaNCT05222555

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) (up to approximately 2 years)Enrollment:53/53Sites: 62NA, TREATMENT

Phase 2Sep 9, 2024EpacadostatSarcomaNCT03414229

Primary: Number of Patients With Best Objective Response Rate (by 24 weeks)Enrollment:30/30Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q1 2025RetifanlimabHead and Neck CancerNCT05287113

Primary: Progeression-free Survival (PFS) (up to 738 days)Enrollment:176/176Sites: 91RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2025INCB000928Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera MyelofibrosisNCT04455841

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE) (up to approximately 4 years)Enrollment:84/84Sites: 34NON_RANDOMIZED, TREATMENT

Phase 2May 1, 2025CapecitabineGastric Adenocarcinoma, Esophageal AdenocarcinomaNCT05177133

Primary: Effect of chemo- and immunotherapy on the interferon gamma expression signature in the tumor microenviornment (40 months)Enrollment:Target 25Sites: 8NA, TREATMENT

Phase 2Jun 30, 2025PelareorepAnatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast CarcinomaNCT04445844

Primary: Objective response rate (ORR) (Within 8 weeks after completion of treatment)Enrollment:Target 25Sites: 2NA, TREATMENT

Phase 2Q3 2025tafasitamabNon Hodgkins Lymphoma, Diffuse Large B-cell LymphomaNCT04661007

Primary: Part 1,2 and 3 : Treatment Emergent Adverse Events (TEAE'S) (Approximately 2 years)Enrollment:72/72Sites: 23NON_RANDOMIZED, TREATMENT

Phase 3Q3 2025INCA034176Chronic Graft-versus-host-diseaseNCT06263478

Primary: Overall Response Rate in the First 6 Cycles (Up to Cycle 7 (Day 169))Enrollment:21/21Sites: 16NA, TREATMENT

Phase 2Sep 25, 2025RuxolitinibChronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic PhaseNCT03610971

Primary: 12 Month Treatment Free Remission (TFR) (12 months post 12 cycles of treatment)Enrollment:24/24Sites: 8NA, TREATMENT

Phase 2Sep 30, 2025TafasitamabCNS Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaNCT05351593

Primary: Proportion of participants with dose limiting toxicities (DLTs) (Phase 1) (Up to 1 cycle (1 cycle is equal to 28 days))Enrollment:Target 35Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Nov 7, 2025RuxolitinibHemophagocytic LymphohistiocytosisNCT04551131

Primary: Complete Response (CR)/Complete Response with Incomplete Hematologic Recovery (CRi) (8 weeks)Enrollment:10/10Sites: 13NON_RANDOMIZED, TREATMENT

Phase 2Q4 2025Ponatinib 15 MGChronic Myeloid Leukemia, Chronic PhaseNCT04160546

Primary: Proportion of patients with a maintained MMR within 52 weeks following ponatinib Treatment-Free Remission (TFR) (52 weeks)Enrollment:Target 80Sites: 13NA, TREATMENT

Phase 2Q1 2026RuxolitinibDuctal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal HyperplasiaNCT02928978

Primary: Change in Apoptosis (15 days (+/- 5 days))Enrollment:84/84Sites: 8RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2026PovorcitinibNon Segmental VitiligoNCT06113445

Primary: Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) (Week 52)Enrollment:467/467Sites: 100RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2026PovorcitinibNon Segmental VitiligoNCT06113471

Primary: Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) (Week 52)Enrollment:450/450Sites: 86RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2026Ruxolitinib Topical CreamExanthema, Lichenoid Skin Rashes Under Anti-PD1 Tumor TherapyNCT06399029

Primary: Proportion of patients achieving at least 90% improvement of rash at week 12. (week 12)Enrollment:22/22Sites: 1NA, TREATMENT

Phase 2Q1 2026DoxorubicinResectable SarcomaNCT04968106

Primary: Assessment of the antitumor activity of retifanlimab when prescribed in association with neoadjuvant chemotherapy (doxorubicin+ifosfamide) (5 months after treatment onset)Enrollment:Target 66Sites: 3RANDOMIZED, TREATMENT

Phase 2Q1 2026RuxolitinibHodgkin LymphomaNCT03681561

Primary: Maximum Tolerated Dose (24 months)Enrollment:Target 54Sites: 6NON_RANDOMIZED, TREATMENT

Phase 3Q2 2026TafasitamabLarge B-Cell Lymphoma, Diffuse Large B-Cell LymphomaNCT05429268

Primary: Overall Response Rate (ORR) (Approximately 24 months)Enrollment:82/82Sites: 61NA, TREATMENT

Phase 2Q2 2026retifanlimabEndometrial CancerNCT04463771

Phase 2May 1, 2026CyclophosphamideB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeNCT05453500

Primary: Rate of minimal residual disease (MRD) (After 1 cycle of treatment (each cycle = 21 days))Enrollment:32/32Sites: 1NA, TREATMENT

Phase 2Q2 2026INCB177054Solid Tumors, Advanced Solid Tumors, Metastatic Solid TumorsNCT06873789

Primary: Number of participants with Dose Limiting Toxicities (DLTs) (Up to 28 days)Enrollment:9/9Sites: 9NON_RANDOMIZED, TREATMENT

Phase 2Q2 2026AxatilimabHodgkin LymphomaNCT05723055

Primary: Objective response rate (ORR) as measured by Best Overall Response Rate (BOR) measured by the proportion of subjects achieving a confirmed PR and CR as defined by Lugano Criteria (At the end of 6 cycles of Treatment. Each cycle is 28 days)Enrollment:Target 9Sites: 2NA, TREATMENT

Phase 2Q2 2026povorcitinibModerate to Severe AsthmaNCT05851443

Primary: Absolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1) (Baseline ; Week 24)Enrollment:247/247Sites: 82RANDOMIZED, DOUBLE, TREATMENT

Phase 2Jun 20, 2026ItacitinibDiffuse Large B Cell LymphomaNCT05757219

Primary: Progression Free Survival (PFS) (at 6 months)Enrollment:Target 27Sites: 1NA, TREATMENT

Phase 2Q2 2026itacitinibMyelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host DiseaseNCT04640025

Phase 2Q2 2026INCMGA00012Well-differentiated/Dedifferentiated LiposarcomaNCT04438824

Primary: confirm the recommended phase two dose (RP2D (within 6 weeks of treatment)Enrollment:42/42Sites: 7NA, TREATMENT

Phase 2Q3 2026INCA034176Chronic Graft-versus-host-diseaseNCT06843408

Primary: Number of participants with Treatment-emergent Adverse Events (TEAEs) (Up to 2 years and 30 days)Enrollment:32/32Sites: 9NA, TREATMENT

Phase 3Q3 2026RuxolitinibAtopic DermatitisNCT06832618

Primary: VC Period: Binary response status of Eczema Area and Severity Index 75 (EASI75) (VC Week 8)Enrollment:159/159Sites: 93RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026INCB099280Advanced Solid TumorNCT05879822

Primary: Objective response rate (ORR) (Up to 2 years)Enrollment:73/73Sites: 54RANDOMIZED, TREATMENT

Phase 2Q3 2026PemigatinibIntrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene MutationNCT06728410

Primary: Confirmed objective response rate (ORR) (24 months)Enrollment:Target 38Sites: 2NA, TREATMENT

Phase 3Q3 2026Ruxolitinib CreamNon Segmental VitiligoNCT06548360

Primary: Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) (Week 24)Enrollment:Target 180Sites: 98RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2026TafasitamabDiffuse Large B-cell LymphomaNCT04824092

Primary: PFS-INV (Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months))Enrollment:899/899Sites: 307RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026INCB099280Cutaneous Squamous Cell CarcinomaNCT05888844

Primary: Objective response rate (ORR) (Up to 2 years)Enrollment:63/63Sites: 77RANDOMIZED, TREATMENT

Phase 2Sep 29, 2026RetifanlimabSoft Tissue Sarcoma, Sarcoma, Soft Tissue, SarcomaNCT04577014

Primary: Phase II: proportion of patients that are progression-free at 24 weeks by RECIST v1.1 (24 weeks)Enrollment:Target 98Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3Sep 30, 2026PrednisoneAcute Lymphoblastic Leukemia, Acute Lymphoblastic LymphomaNCT03117751

Primary: Event-free survival of ALL patients (EFS) (At 3.5 years after enrollment of the last participant)Enrollment:790/790Sites: 8RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2026Ruxolitinib CreamHidradenitis SuppurativaNCT06958211

Primary: Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline (Week 16)Enrollment:573/573Sites: 107RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026Ruxolitinib CreamHidradenitis SuppurativaNCT06959225

Primary: Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline (Week 16)Enrollment:580/580Sites: 101RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026PovorcitinibPrurigo NodularisNCT06516965

Primary: Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24 (Week 24)Enrollment:346/346Sites: 119RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2026PovorcitinibPrurigo NodularisNCT06516952

Primary: Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24 (Week 24)Enrollment:349/349Sites: 120RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ4 2026Ruxolitinib 1.5% CreamHidradenitis SuppurativaNCT04414514

Primary: Number of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR) (16 weeks after treatment.)Enrollment:6/6Sites: 1NA, TREATMENT

Phase 2Q4 2026ParsaclisibB-Cell MalignanciesNCT04509700

Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (Through study completion, an average of 5 years)Enrollment:112/112Sites: 105NON_RANDOMIZED, TREATMENT

Phase 2Dec 1, 2026PembrolizumabTNBC - Triple-Negative Breast Cancer, Breast CancerNCT05491226

Primary: Pathological complete response (pCR) rate. (From treatment start date until the time of curative-intent treatment, approximately 7 weeks.)Enrollment:Target 35Sites: 1NA, TREATMENT

Phase 3Q4 2026PovorcitinibHidradenitis Suppurativa (HS)NCT06212999

Primary: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) (up to approximately 56 weeks)Enrollment:617/617Sites: 165RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Dec 31, 2026RuxolitinibT-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-CellNCT07356245

Primary: Cumulative Incidence (CI) of relapse (at 1-year post-auto-SCT)Enrollment:Target 44Sites: 1NA, TREATMENT

Phase 2Dec 31, 2026PemigatinibAdvanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8NCT06906562

Primary: Overall Response Rate (ORR) (Up to 24 months)Enrollment:Target 40Sites: 109NA, TREATMENT

Phase 2Dec 31, 2026LenalidomideGrade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsNCT05890352

Primary: Progression-free survival (PFS) (From date of randomization to date of first observation of progressive disease according to the 2014 Lugano classification, or death due to any cause, assessed up to 3 years)Enrollment:Target 227Sites: 104RANDOMIZED, TREATMENT

Phase 2Jan 1, 2027RuxolitinibSplenomegaly, MyelofibrosisNCT06345495

Primary: Safety and adverse events (AEs) (Through study completion; an average of 1 year.)Enrollment:Target 30Sites: 1NA, TREATMENT

Phase 2Q1 2027PemigatinibRelapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaNCT06300528

Primary: Overall Response Rate (ORR) at Cycle 7 per IWG Response Criteria in subjects with R/R MCL. (8 months)Enrollment:1/1Sites: 1NA, TREATMENT

Phase 2Q1 2027TafasitamabLarge B-cell LymphomaNCT06760156

Primary: Complete Response Rate (CRR) (Up to 3 months)Enrollment:Target 28Sites: 1NA, TREATMENT

Phase 2Jan 31, 2027RetifanlimabUnresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell CarcinomaNCT06056895

Primary: Objective response rate (Up to 5 years following completion of study treatment)Enrollment:12/12Sites: 1NA, TREATMENT

Phase 2Feb 6, 2027topical ruxolitinib 1.5% creamNon-sclerotic Cutaneous Chronic Graft-versus-host DiseaseNCT03954236

Primary: Reduction in Body Surface Area (BSA) From Day 1 and Day 28 (28 days (+/-3 days))Enrollment:24/24Sites: 1NA, TREATMENT

Phase 2Q1 2027TafasitamabNon-Hodgkin LymphomaNCT05583071

Primary: complete response rate (CRR) (At the end of cycle 2 (each cycle is 21 days))Enrollment:Target 20Sites: 6NA, TREATMENT

Phase 2Q1 2027RuxolitinibMyelofibrosisNCT03069326

Primary: best objective response rate (ORR) (1 year)Enrollment:30/30Sites: 7NON_RANDOMIZED, TREATMENT

Phase 2Apr 1, 2027BusulfanHematologic and Lymphocytic DisorderNCT04859946

Primary: Incidence of acute grade 2-4 graft versus host disease (GVHD) (At 100 days after stem cell transplant)Enrollment:Target 31Sites: 1NA, SUPPORTIVE_CARE

Phase 2Apr 1, 2027AxatilimabAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid NeoplasmNCT06320405

Primary: Incidence of dose limiting toxicities (phase Ib) (From the first dose of axatilimab (day -8) to the end of cycle 1 (cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel]))Enrollment:Target 38Sites: 1NA, TREATMENT

Phase 2Q2 2027INCB123667Ovarian CancerNCT07023627

Primary: Objective Response by IRC (Up to 2 years)Enrollment:Target 160Sites: 74NON_RANDOMIZED, TREATMENT

Phase 3Q2 2027Ruxolitinib CreamNon Segmental VitiligoNCT06804811

Primary: Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) (Week 24)Enrollment:Target 250Sites: 78RANDOMIZED, TRIPLE, TREATMENT

Phase 2Jun 1, 2027RuxolitinibLeukemia, Myelodysplasia, Chronic Myelomonocytic LeukemiaNCT07249346

Phase 2Jun 1, 2027RetifanlimabGlioma, IDH Mutation, AstrocytomaNCT05345002

Phase 2Q2 2027AxatilimabChronic Graft-versus-host-diseaseNCT06388564

Phase 2Jun 1, 2027RuxolitinibAcute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse EffectsNCT06936566

Phase 2Jun 30, 2027PemigatinibSolid Tumor, MiscellaneousNCT06653777

Phase 2Jul 15, 2027EpacadostatRectal CancerNCT03516708

Phase 2Q3 2027INCB000928Fibrodysplasia Ossificans Progressiva (FOP)NCT05090891

Phase 2Q3 2027RuxolitinibEssential Thrombocythemia, Polycythemia VeraNCT04644211

Phase 2Q3 2027TafasitamabHematologic MalignanciesNCT06465433

Phase 2Q3 2027ASTX727MDS/MPNNCT04061421

Phase 2Q3 2027INCA000585Immune ThrombocytopeniaNCT07104565

Phase 3Q3 2027INCA034176Chronic Graft-versus-host-diseaseNCT06585774

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 2Q3 2027RuxolitinibPancreatic Cancer, Colorectal Cancer (CRC), Breast CancerNCT02955940

Phase 2Oct 31, 2027AxatilimabAtypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative NeoplasmNCT06523556

Phase 2Q4 2027RuxolitinibNon Small Cell Lung Carcinoma, Renal Cell CarcinomaNCT07219576

Phase 2Dec 31, 2027RuxolitinibHemophagocytic LymphohistiocytosesNCT06160791

Phase 2Dec 31, 2027CyclosporineAplastic AnemiaNCT06752694

Phase 2Jan 30, 2028EnzalutamideCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8NCT06616155

Phase 2Q1 2028RuxolitinibNon-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ RelapsedNCT07283822

Phase 2Q1 2028UlixertinibMyelofibrosisNCT06773195

Phase 2Q1 2028PonatinibAcute Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blast Phase Chronic Myeloid LeukemiaNCT03934372

Phase 2Feb 22, 2028PemigatinibAdvanced Cholangiocarcinoma, FGFR2 FusionNCT06439485

Phase 3Q1 2028povorcitinibHidradenitis Suppurativa (HS)NCT06855498

Phase 2Q1 2028PovorcitinibHidradenitis Suppurativa (HS)NCT07213973

Phase 2May 1, 2028ZanubrutinibMantle Cell LymphomaNCT06029309

Phase 3Q2 2028INCA034176Chronic Graft-versus-host-diseaseNCT06821542

Phase 2Q2 2028Conditioning Regimen AAML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)NCT06859424

Phase 2Aug 10, 2028AxatilimabChronic Graft Versus Host DiseaseNCT07011810

Phase 2Q3 2028EpcoritamabLymphomaNCT07030699

Phase 3Q3 2028INCB161734Solid TumorsNCT07522073

Phase 2Oct 1, 2028PemigatinibSDH Gene Mutation, Gastrointestinal Stromal TumorNCT07434843

Primary: Objective radiographic response rate (From first dose of pemigatinib until the date of objective response per RECIST 1.1 through study completion, an average of 1 year)Enrollment:Target 24Sites: 1NA, TREATMENT

Phase 3Q4 2028INCB123667Ovarian CancerNCT07214779

Phase 2Nov 19, 2028RuxolitinibSickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell TransplantNCT07252050

Phase 3Q4 2028INCA33890CRC (Colorectal Cancer)NCT07284849

Phase 2Dec 30, 2028RuxolitinibBCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated CellsNCT03801434

Phase 2Q4 2028RuxolitinibChronic Graft-versus-host Disease (c GVHD)NCT06660355

Phase 2Dec 31, 2028RuxolitinibCastleman's Disease (CD), Idiopathic Multicentric Castleman's DiseaseNCT07085039

Phase 2Q1 2029INCA034176Chronic Graft-versus-host-diseaseNCT07124078

Phase 2Q1 2029ChemotherapyAnal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the AnusNCT07425054

Phase 2Q1 2029CyclophosphamideHematologic MalignanciesNCT07359859

Phase 2Q2 2029INCA33890CRC (Colorectal Cancer)NCT07823322

Phase 3Q2 2029INCA033989Essential ThrombocythemiaNCT07623200

Phase 2Jul 8, 2029TafasitamabFollicular Lymphoma, Marginal Zone LymphomaNCT06792825

Phase 2May 5, 2030AxatilimabChronic Graft Versus Host Disease, c GVHDNCT06663722

Phase 3Q3 2030parsaclisibMantle Cell LymphomaNCT04849715

Phase 2Sep 1, 2030RuxolitinibMyelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary MyelofibrosisNCT07228624

Phase 2Q4 2030RuxolitinibGlioblastoma, Brain Cancer, Glioblastoma MultiformeNCT06991101

Phase 3Q1 2031Tacrolimus (Tac)Graft-versus-host Disease (GVHD)NCT06615050

Phase 2Q1 2031PemigatinibUnresectable Cholangiocarcinoma, Advanced/Metastatic CholangiocarcinomaNCT07862998

Phase 2Jul 31, 2031Axatilimab (SNDX-6352)Myelofibrosis (MF), Chronic Myelomonocytic Leukemia (CMML)NCT07128381

Phase 2Q4 2031EpcoritamabLarge B Cell LymphomaNCT07126236

Phase 3Q2 2032INCB123667Ovarian CancerNCT07797283

Phase 2Q4 2032PembrolizumabTNBC - Triple-Negative Breast Cancer, Breast CancerNCT07015853

Incyte Corporation

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research